Merit Medical

Canaccord Genuity acts as financial advisor to Merit Medical Systems, Inc. on its purchase of HeRO Graft from CryoLife, Inc.

Canaccord Genuity is pleased to announce that on February 4, 2016, Merit Medical Systems, Inc. (Nasdaq: MMSI), a worldwide designer, developer, manufacturer, and marketer of medical devices used in interventional and diagnostic procedures, has agreed to purchase the HeRO Graft device and related assets from CryoLife, Inc. for $18.5 million in cash.

CryoLife’s HeRO Graft product line is a fully subcutaneous AV access solution clinically proven to maintain long-term access for hemodialysis patients with central venous stenosis.  It is classified by the FDA as a vascular graft prosthesis and offers key benefits such as fewer infections, superior dialysis adequacy, high patency rate, and cost savings.

Canaccord Genuity acted as financial advisor to Merit Medical Systems and its Board of Directors in connection with the transaction.

Merit Medical Systems designs, develops, manufactures, and markets medical devices for interventional and diagnostic procedures worldwide.  The Company’s cardiovascular segment offers cardiology and radiology devices and embolotherapeutic products.  The Company also has an endoscopy segment which provides gastroenterology and pulmonology medical devices.

CryoLife is a leader in the manufacturing, processing, and distribution of implantable living tissues and medical devices used in cardiac and vascular surgical procedures.  CryoLife markets and sells products in more than 75 countries worldwide.